Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

Biologics revolutionize generalized myasthenia gravis care with fast-acting, patient-friendly therapies and a robust global pipeline redefining outcomes. The gMG treatment era is shifting rapidly-from ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications. While existing C5 inhibitors have contributed to ...

Judith Rae Carr died on May 27 2025 at the age of 84 in San Francisco, California at the Van Ness Campus of California Pacific Medical Center of pneumonia and myasthenia gravis ... Despite the fears ...

This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG ... struggle to manage the debilitating symptoms of this rare autoimmune disease." ...

Does anyone really listen to prescription drug commercials on television? Virtually all these ads come with a long list of scary side effects. It’s hard to believe that people would badger their ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...